503B outsourcing facility
A 503B outsourcing facility is an FDA-registered manufacturer that compounds large batches of medications without patient-specific prescriptions, under full current Good Manufacturing Practice (cGMP) requirements.
- Created by the Drug Quality and Security Act of 2013
- FDA-registered and inspected under full cGMP
- Compounds in bulk without patient-specific prescriptions
- Works from its own 503B bulks list, separate from 503A’s
What makes 503B different from a regular compounding pharmacy?
Section 503B, added by the Drug Quality and Security Act of 2013 after the NECC meningitis outbreak, created a category between traditional pharmacy and pharmaceutical manufacturer. A 503B facility registers directly with the FDA, follows the same cGMP quality standards as drug manufacturers, is inspected by the FDA on a risk-based schedule, and may compound in bulk — no individual prescription required at the time of compounding.
The result is scale with oversight: hospitals, clinics, and med spas buy 503B-compounded products as office stock, something a 503A pharmacy generally cannot supply.
Why 503B matters for telehealth and clinic programs
If your care model administers medication in person — an infusion clinic, a med spa offering injections, an in-office program — your inventory typically needs to come from a 503B facility, because office stock without patient-specific prescriptions is exactly what 503A cannot do. If your model ships prescriptions to patients at home, 503A pharmacies are usually the fulfillment path, with 503B supplying any clinic-administered arm of the business.
The 503B bulks list is separate from the 503A list, and a substance’s status can differ between them — a nuance that regularly trips up program design.
How programs combine 503A and 503B
The two categories are complements, not competitors. A typical national telehealth program pairs 503A pharmacies for ship-to-patient prescriptions with a 503B supplier for any clinic-administered arm — and some operators source the same molecule both ways for different channels.
Operationally, 503B adds manufacturer-grade discipline: batch records, stability testing, and release timelines. That means lead times and minimum orders a 503A relationship does not have — worth planning for if your clinic channel grows faster than your mail channel.
What cGMP looks like day to day
The difference between a 503B and a large 503A is not scale alone — it is manufacturing discipline. Every batch gets a batch record documenting each step and signature. Clean rooms run continuous environmental monitoring. Products carry expiration dates backed by formal stability studies rather than conservative beyond-use dates. Release testing clears each lot before it ships, and recall procedures exist because the FDA expects to see them exercised. That discipline is what lets hospitals and clinics stock 503B product on the shelf.
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
Are 503B compounded drugs FDA-approved?
No. 503B facilities are FDA-registered and cGMP-regulated, but the compounded products themselves are not FDA-approved drugs.
Can a 503B facility fill individual patient prescriptions?
Yes, it may — but its defining ability is compounding without patient-specific prescriptions, which is what enables office stock.
Does a telehealth company need a 503B partner?
Only if part of the model involves clinic-administered or office-stocked medication. Ship-to-patient prescription programs typically run on licensed 503A pharmacies.